Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has treated its first patient using genetically modified T-cells that were manufactured in its own state-of-the-art Good Manufacturing Practices (GMP) facility, a fully commissioned clean space for manufacturing of viral vectors and cell products for human administration. Read More
Christian S. Hinrichs, MD, chief of Cancer Immunotherapy and co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute.
Steven K. Libutti, MD, FACS, Rutgers Cancer Institute Director, who is also the senior vice president of oncology services at RWJBarnabas Health.